Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination

Myocarditis is an adverse event associated with coronavirus disease 2019 (COVID‐19) mRNA vaccination. A 50‐year‐old man presented with dyspnea and resting chest pain after receiving the second dose of the COVID‐19 mRNA vaccine and developed cardiogenic shock. Fulminant myocarditis was diagnosed by e...

Descripción completa

Detalles Bibliográficos
Autores principales: Oka, Akihiro, Sudo, Yuya, Miyoshi, Toru, Ozaki, Masatomo, Kimura, Yuta, Takagi, Wataru, Ugawa, Satoko, Okada, Tomoaki, Nosaka, Kazumasa, Doi, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819635/
https://www.ncbi.nlm.nih.gov/pubmed/35154722
http://dx.doi.org/10.1002/ccr3.5378
_version_ 1784646092216860672
author Oka, Akihiro
Sudo, Yuya
Miyoshi, Toru
Ozaki, Masatomo
Kimura, Yuta
Takagi, Wataru
Ugawa, Satoko
Okada, Tomoaki
Nosaka, Kazumasa
Doi, Masayuki
author_facet Oka, Akihiro
Sudo, Yuya
Miyoshi, Toru
Ozaki, Masatomo
Kimura, Yuta
Takagi, Wataru
Ugawa, Satoko
Okada, Tomoaki
Nosaka, Kazumasa
Doi, Masayuki
author_sort Oka, Akihiro
collection PubMed
description Myocarditis is an adverse event associated with coronavirus disease 2019 (COVID‐19) mRNA vaccination. A 50‐year‐old man presented with dyspnea and resting chest pain after receiving the second dose of the COVID‐19 mRNA vaccine and developed cardiogenic shock. Fulminant myocarditis was diagnosed by endomyocardial biopsy and treated with intravenous corticosteroids.
format Online
Article
Text
id pubmed-8819635
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88196352022-02-11 Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination Oka, Akihiro Sudo, Yuya Miyoshi, Toru Ozaki, Masatomo Kimura, Yuta Takagi, Wataru Ugawa, Satoko Okada, Tomoaki Nosaka, Kazumasa Doi, Masayuki Clin Case Rep Case Reports Myocarditis is an adverse event associated with coronavirus disease 2019 (COVID‐19) mRNA vaccination. A 50‐year‐old man presented with dyspnea and resting chest pain after receiving the second dose of the COVID‐19 mRNA vaccine and developed cardiogenic shock. Fulminant myocarditis was diagnosed by endomyocardial biopsy and treated with intravenous corticosteroids. John Wiley and Sons Inc. 2022-02-07 /pmc/articles/PMC8819635/ /pubmed/35154722 http://dx.doi.org/10.1002/ccr3.5378 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Oka, Akihiro
Sudo, Yuya
Miyoshi, Toru
Ozaki, Masatomo
Kimura, Yuta
Takagi, Wataru
Ugawa, Satoko
Okada, Tomoaki
Nosaka, Kazumasa
Doi, Masayuki
Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
title Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
title_full Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
title_fullStr Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
title_full_unstemmed Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
title_short Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
title_sort fulminant myocarditis after the second dose of covid‐19 mrna vaccination
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819635/
https://www.ncbi.nlm.nih.gov/pubmed/35154722
http://dx.doi.org/10.1002/ccr3.5378
work_keys_str_mv AT okaakihiro fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT sudoyuya fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT miyoshitoru fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT ozakimasatomo fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT kimurayuta fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT takagiwataru fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT ugawasatoko fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT okadatomoaki fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT nosakakazumasa fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination
AT doimasayuki fulminantmyocarditisaftertheseconddoseofcovid19mrnavaccination

Ejemplares similares